Introduction: Antenatal prophylaxis including Sulphadoxine-pyrimethamine (SP), mebendazole and iron and folic acid (FeFol) are provided to pregnant women aiming to correct/prevent the occurrence of adverse outcomes of pregnancy. These antenatal prophylaxis aims to combat the effects of maternal infections like malaria and hookworm and iron deficiency anaemia. Globally, about 40% of pregnant women are estimated to have iron deficiency anaemia and thus FeFol are recommended to pregnant women at least 4-month prior pregnancy, during pregnancy and postpartum period. IPT for pregnant women consists of two doses of sulphadoxine-pyrimethamine (SP) (1500/75 mg), administered at scheduled clinic visits at least one month apart, starting in the second trimester. IPTp-SP aims to prevent severe malaria considering women are vulnerable for malaria infection and may not always present clinically. However, the proportion of pregnant women who receive ≥two doses of IPT-SP in sub-Saharan Africa remains relatively low, below 60%. Intestinal worms are common in developing countries including pregnant population, about 44 million pregnancies a year are complicated by maternal hookworm infection alone, posing a serious threat to the health of mothers and fetuses mainly associated to anaemia. The latter may justify need of deworming pregnant women. Objective: To determine prevalence of antenatal prophylaxis uptake and birth outcomes among pregnant women delivered at Majengo and Pasua health centers Methodology: This was a cross sectional study conducted at Majengo and Pasua health centers from May to June, 2016. Pregnant women who delivered in these facilities were recruited for the study. Data was collected using a questionnaire. Categorical data was summarized by using frequency and proportions and presented by pie charts. Quantitative data was summarized by tables and presented by histograms. Results A total of 191 women were recruited for the study. Those mother who aged between 31-49 years have 5.37 odds of using mebendazole compared to those who aged below 20 years old, those mothers from rural have 2.67 odds of using mebendazole. women who come from urban area are 88% of using FeFol tablets as compared to those who came from rural areas, (OR=0.88; 95%CI 0.5-1.7) and there is negative association between self-employed and formal employed women in vii the sense that those women who are self-employed are 26% less likely to use FeFol than those women who are formally employed, (OR=0.74;95%CI 0.2-2.4). women who are not married are 34% more likely to use IPTp-SP as compared to those women who are married, (OR=1.34; 95%CI 0.5-3.5). there is positive association between those women who didn’t use FeFol and IPTp-SP tablets with low birthweight(<2500gms).those women who didn’t uses FeFol are 49% more likely to deliver low birthweight baby compared to those who uses FeFol, (OR=1.49;95%CI 0.8-2.8 ) and those women who didn’t uses IPTp-SP tablets have 2.09 Odds of delivering low birth baby compared to those who did use IPTp-SP tablets during pregnancy, (OR=2.09;95%CI 1.0-4.6).How ever there is neither association is statistical significant between two prophylaxes. Conclusion: There are importance benefits of using antenatal prophylaxes especially FeFol and IPTp-SP during pregnancy period according to the guidelines available. Also the findings of this study opens door for the other multicenter study to be conducted in order to add more value.